Side-by-side · Research reference
GDF-8vsLL-37
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/48 cited
BHuman-MechanisticHUMAN-REVIEWED15/35 cited
GDF-8
TGF-β Superfamily · Negative Muscle Regulator
15–20%Muscle mass gain (MSTN−/−)
Not administered — research target for inhibition
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
01Mechanism of Action
Parameter
GDF-8
LL-37
Primary target
Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026
Pathway
MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026Iglesias 2026
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Feedback intact?
Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026
—
Origin
Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Antibody development
—
—
02Dosage Protocols
Parameter
GDF-8
LL-37
Clinical use
None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans
Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.
—
Inhibition strategies
Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)
—
VLP immunogen (MS2.87-97)
Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026
Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026
—
Dual immunization (MSTN + Activin A)
Combined active immunization in GH-deficient miceMansoor 2026
Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026
—
Gene editing outcomes
Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock
Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.
—
Endogenous expression
—
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
—
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
Plasma levels (malaria)
—
Evidence basis
—
In vitro, animal models, human observational
03Metabolic / Fat Loss Evidence
Parameter
GDF-8
LL-37
Primary mechanism
MSTN loss-of-function reduces fat accumulation independent of muscle mass effects
—
Human genetic evidence
Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026
—
Animal model outcomes
VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026
—
Adipose-muscle crosstalk
MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026
—
Age-related effects
MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation
—
04Side Effects & Safety
Parameter
GDF-8
LL-37
Genetic null phenotype
No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026
—
Antibody cross-reactivity risk
Non-selective inhibitors may block GDF11, affecting cardiac and neural function
—
VLP immunotherapy safety
No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026
—
Pleiotropic effects (gene editing)
MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare
—
Assay variability
Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026
—
Cytotoxicity (high dose)
—
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
—
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Theoretical cancer risk
—
Immunomodulatory roles in tumor microenvironment under investigation
Absolute Contraindications
GDF-8
- ·Not applicable — MSTN is not administered as a therapeutic agent
LL-37
—Relative Contraindications
GDF-8
- ·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
05Administration Protocol
Parameter
GDF-8
LL-37
1. Research context only
GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
2. Inhibition strategies
Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
3. VLP immunization protocol (animal model)
MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
4. Gene editing considerations
CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.
—